Sanofi Cash on Hand 2010-2023 | SNY

Sanofi cash on hand from 2010 to 2023. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
  • Sanofi cash on hand for the quarter ending December 31, 2023 was $9.427B, a 29.75% decline year-over-year.
  • Sanofi cash on hand for 2023 was $9.427B, a 29.75% decline from 2022.
  • Sanofi cash on hand for 2022 was $13.419B, a 12.32% increase from 2021.
  • Sanofi cash on hand for 2021 was $11.947B, a 24.84% decline from 2020.
Sanofi Annual Cash on Hand
(Millions of US $)
2023 $9,427
2022 $13,419
2021 $11,947
2020 $15,895
2019 $10,558
2018 $8,178
2017 $11,659
2016 $11,368
2015 $10,281
2014 $10,048
2013 $11,214
2012 $8,436
2011 $5,985
2010 $8,653
2009 $6,930
Sanofi Quarterly Cash on Hand
(Millions of US $)
2023-12-31 $9,427
2023-09-30
2023-06-30 $8,716
2023-03-31
2022-12-31 $13,419
2022-09-30
2022-06-30 $7,342
2022-03-31
2021-09-30
2021-03-31
2020-09-30
2020-03-31
2019-09-30
2019-03-31
2018-03-31
2017-12-31 $11,659
2017-09-30
2017-06-30 $11,967
2017-03-31
2016-12-31 $11,368
2016-09-30
2016-06-30 $7,010
2016-03-31
2015-09-30
2015-06-30 $5,450
2014-06-30 $6,000
2013-06-30 $5,567
2012-06-30 $5,960
2012-03-31
2011-12-31 $5,985
2011-09-30
2011-06-30 $9,573
2011-03-31
2010-12-31 $8,653
2010-09-30
2010-06-30 $4,341
2010-03-31
2009-12-31 $6,930
2009-09-30
2009-06-30 $8,722
2009-03-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $120.637B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $708.528B 117.99
Novo Nordisk (NVO) Denmark $577.276B 47.56
Johnson & Johnson (JNJ) United States $360.407B 14.30
Merck (MRK) United States $321.391B 84.59
AbbVie (ABBV) United States $300.196B 15.26
AstraZeneca (AZN) United Kingdom $219.666B 19.46
Novartis AG (NVS) Switzerland $198.840B 14.10
Pfizer (PFE) United States $149.038B 14.38
Innoviva (INVA) United States $0.959B 6.77